Last reviewed · How we verify
Red yeast rice
Red yeast rice, marketed by Dr. Laurence Klotz, is a dietary supplement with a presence in the cholesterol management market. The key composition patent is set to expire in 2028, which may provide a competitive advantage by delaying generic competition. However, the lack of a clear primary indication and revenue data poses a significant risk in assessing its market impact and financial performance.
At a glance
| Generic name | Red yeast rice |
|---|---|
| Also known as | Aliperol |
| Sponsor | Dr. Laurence Klotz |
| Drug class | Standardized Chemical Allergen [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Red Yeast Rice for Primary Prevention of Hypercholesterolemia
- Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose (NA)
- Effect of ANKASCIN 568-P Products Regulating Blood Lipid (NA)
- Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome (EARLY_PHASE1)
- Extracts of Amla, Walnut Leaf, Red Yeast Rice and Olive in Cardiovascular Prevention (PHASE4)
- Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia (NA)
- Patient Autonomy and Statin Therapy Adherence (NA)
- The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Red yeast rice CI brief — competitive landscape report
- Red yeast rice updates RSS · CI watch RSS
- Dr. Laurence Klotz portfolio CI